Speedier processes, cost reduction and the personalization of therapeutics are at the forefront among many of the challenges involved for drug discovery and development. The recent advances in both biomarker development and next generation sequencing have provided promising opportunities to overcoming such challenges.
Biomarkers are a dynamic and potent tool in understanding the predication, cause, diagnosis, progression, regression, or outcome of the treatment of diseases. They also play a critical role in lead discovery and optimization, target validation, animal models, drug safety assessment and clinical trials.
Next generation sequencing technologies have dramatically increased the speed and reduced costs of sequencing. These technologies have made it possible to compare genetic sequences among multiple genomes; data comparisons between individual patients, populations, or normal and pathologic cells are now a reality.
GTC’s Drug Discovery Week Europe (DDWE) will have over 400 attendees with conferences covering biomarker research, biomarker development, next generation sequencing and bioinformatics.
DDWE will comprise of four conferences across four days:
IV. Biomarkers in Diagnostics